2018 Oncology Pharmacy Specialty Home Study Syllabus for Recertification, Volume 1: Chronic Pain Management, Sarcoma, Oncology Pharmacy Administration Learning Objectives

Chronic Pain Management
1. Assess pain in survivors of adult cancer.
2. Appraise and mitigate the risk of opioid use in survivors of adult cancer with chronic pain.
3. Develop a treatment plan to manage chronic pain in survivors of adult cancer.

Sarcoma
1. Compare and contrast the mechanism of action and toxicities of ifosfamide and evofosfamide.
2. Determine the clinical role of combination therapy with doxorubicin and evofosfamide in the treatment of soft tissue sarcoma.
3. Explore the toxicities associated with evofosfamide and doxorubicin compared with doxorubicin alone.

Oncology Pharmacy Administration
1. Appraise the landscape of drug databases to use for assessing drug-drug interactions with oral oncolytics.
2. Analyze the study methodology used by the investigators to conduct this study.
3. Interpret the study findings and how they relate to oncology pharmacist decision-making when evaluating clinical drug-drug interactions with oral oncolytics.
4. Discuss limitations in broadly applying these data to clinical practice in oncology pharmacy practice.

2018 Oncology Pharmacy Specialty Home Study Syllabus for Recertification, Volume 1: Ovarian Cancer, Oncology Drug Literature: Biostatistics and Study Design, Head and Neck Cancer, Urothelial Carcinoma Learning Objectives

Ovarian Cancer
1. Apply, evaluate, and interpret the findings of the ENGOT-OV16/NOVA trial to patients with recurrent ovarian cancer.
2. Use patient-specific clinical data to design and justify appropriate therapeutic treatment recommendations for patients with ovarian cancer.
3. Differentiate the toxicity profile of niraparib for other health care providers, patients, and caregivers.

Oncology Drug Literature: Biostatistics and Study Design
1. Define confidence interval, p value, power, and different types of hypotheses.
2. Interpret the results of an oncology clinical trial using power, confidence intervals, and p values.
3. Critique a randomized trial with respect to statistical analyses.

Head and Neck Cancer
1. Evaluate the outcomes and toxicities of nivolumab compared with the current standard of care in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
2. Formulate counseling points for a patient with recurrent or metastatic squamous cell carcinoma of the head and neck who plans to start therapy with nivolumab.
3. Assess the biomarkers associated with the response to nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Urothelial Carcinoma
1. Explain the current strategies for the treatment of advanced bladder cancer.
2. Discuss the characteristics of patients who are most likely to benefit from pembrolizumab.
3. Describe the dosing, administration, and toxicity profile of pembrolizumab that patients may experience.
4. Describe the efficacy of pembrolizumab in advanced urothelial cancer.